Pear Therapeutics, a company engaged in developing and commercializing prescription digital therapeutics, went public via a SPAC merger with Thimble Point Acquisition in a $1.2bn deal. Investors in PIPE include 5AM Ventures, Arboretum Ventures, Blue Water Advisors, dRx Capital, The Eleven Fund, FORTH Management, Health Innovation Capital, JAZZ Venture Partners, Neuberger Berman funds, Palantir, Pilot House, Pritzker Vlock Family Office, QUAD Investment, Sarissa Capital, Shanda Group, SoftBank VF 2, Temasek, and Trustbridge Partners. “As a public company, we aim to accelerate our vision to increase access to PDTs by further commercializing our three FDA-authorized PDTs, expanding public and private payer adoption, and advancing our pipeline of PDTs. Thanks to all of our investors for supporting our successful transition," Corey McCann, Pear President and CEO.